Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs

First-in-human Phase 1 study of the SOS1 inhibitor BAY 3498264 administered alone and in combination with sotorasib in participants with advanced KRASG12C-mutated solid tumors

Funder NIHR (part of DHSC)
Recipient organisation NIHR Biomedical Research Centre at the Royal Marsden and the ICR Source-published name: NIHR Royal Marsden Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Nov 2028

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Anna Minchom (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Phase 1 study of a SOS1 inhibitor, BAY 3498264, in combination in participants with advanced KRASG12C-mutated solid tumors
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies
Novel allosteric inhibitors of SOS-mediated mutant Ras-driven tumorigenesis
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of IMP in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Original classification

Early Phase Drug Development

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.